Showing results (1061-1070 of 1,835) with videos related to
Sort By:
Pageof 184
Onkologie|September 28, 2001
Palliation by intratumoral infiltration with natural interferon-betaE Musch, M Malek, G Lammering, et al.Onkologie|March 11, 2011
[Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies]Wolf-Dieter Ludwig, Jan SchildmannOnkologie|March 31, 2011
Prognostic factors and survival in stomach cancer - analysis of 15 years of data from a referral hospital in iran and evaluation of international variationHossein Khedmat, Mohammad Panahian, Mehrdad Mashahdian, et al.Onkologie|March 2, 2011
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trialMichael A Ströhlein, Florian Lordick, Dominik Rüttinger, et al.Onkologie|March 2, 2011
Retrospective analyses of patient characteristics having predictive impact on survival under everolimusChristoph Seidel, Martin Fenner, Christoph Reuter, et al.Onkologie|March 2, 2011
Clinical aspects, diagnostic challenges and management of patients with neuroendocrine tumors (NETs)Gilbert Spizzo, Karin Bernardini, Oreste Pieramico, et al.Onkologie|August 1, 1990
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron]N W Marschner, M Adler, F Jaenicke, et al.Onkologie|October 1, 1990
[Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F]A du Bois, H G Meerpohl, C Wilhelm, et al.Onkologie|October 1, 1990
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]H Serve, M Perker, A Ertl, et al.Pageof 184